MAPK3 and head and neck squamous cell carcinoma: We did not observe any concomitant upregulation of Erk1/2 expression in response to erastin, but the Erk inhibitor, ravoxertinib, downregulated ROS levels and lipid peroxidation in HNSCC cells.